BCPC is the ticker symbol for BALCHEM CORP, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks BCPC with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is BCPC a good stock to buy?

13F Pro's AI ranking engine scores BCPC at 63.9/100, ranked #578 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for BCPC is available at https://13fpro.ai/company/BCPC. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source BCPC data?

All BALCHEM CORP fundamentals and ownership data come directly from SEC EDGAR. BALCHEM CORP files with the SEC under CIK 9326. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

BALCHEM CORP BCPC

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #578 of 2,925TOP 25%

Why it scores 64 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$290.66M

Quarter to Sep 30

Net income

$46.73M

Quarter to Sep 30

Free cash flow

$57.30M

Quarter to Sep 30

Operating margin

21.5%

Quarter to Sep 30

Top Institutional Holders

as of Q2 2026

$4.88B total

BlackRock, Inc.

$838.75M+2.5%

VANGUARD PORTFOLIO MANAGEMENT LLC

$375.28M+1.3%

VANGUARD CAPITAL MANAGEMENT LLC

$244.20M+0.9%

STATE STREET CORP

$216.52M+3.3%

GEODE CAPITAL MANAGEMENT, LLC

$189.61M+7.2%

Conestoga Capital Advisors, LLC

$183.80M-13.1%

WASATCH ADVISORS LP

$177.53M-26.2%

MORGAN STANLEY

$140.98M-2.7%

GENEVA CAPITAL MANAGEMENT LLC

$115.41M-19.3%

FIRST TRUST ADVISORS LP

$104.28M+36.2%

DIMENSIONAL FUND ADVISORS LP

$103.07M+2.2%

FMR LLC

$94.66M-6.4%

CONGRESS ASSET MANAGEMENT CO /MA

$84.91M+12.7%

TWO SIGMA INVESTMENTS, LP

$84.82M+16.7%

SCHRODER INVESTMENT MANAGEMENT GROUP

$74.52M+22.2%

Nuveen, LLC

$70.01M+5.3%

NORGES BANK

$69.59M--

NORTHERN TRUST CORP

$64.91M+2.7%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$63.29M+1.4%

JPMORGAN CHASE & CO

$58.06M-20.0%

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

$53.06M-0.4%

THRIVENT FINANCIAL FOR LUTHERANS

$48.97M+298.0%

GOLDMAN SACHS GROUP INC

$45.96M+61.6%

Stephens Investment Management Group LLC

$45.70M+1.7%

Clearbridge Investments, LLC

$41.18M-5.1%

See all 420 institutional holders →

What's Driving BCPC's Business? Latest 10-Q Breakdown

28/28 datapoints verified

AI-extracted from the 10-Q filed 2026-10-23 — Q3 FY2026 (quarter ended September 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Balchem's Q3 2026 net sales rose 8.6% to $290.7M and net earnings rose 16.0% to $46.7M, led by Human Nutrition & Health sales growth of 8.1%.

Biggest Revenue Drivers

Human Nutrition & Health$188.2M+8.1% YoY

Higher sales within both the nutrients business and the food ingredients and solutions businesses; volume and mix contributed 12.7%.

Animal Nutrition & Health$63.0M+11.7% YoY

Higher sales in both monogastric and ruminant species markets; average selling prices contributed 8.5%.

Biggest Revenue Drivers

Total revenue: $290.7M+8.6% YoY

Human Nutrition & Health$188.2M+8.1% YoY

Higher sales within both the nutrients business and the food ingredients and solutions businesses; volume and mix contributed 12.7%.

Animal Nutrition & Health$63.0M+11.7% YoY

Higher sales in both monogastric and ruminant species markets; average selling prices contributed 8.5%.

Specialty Products$37.3M+4.5% YoY

Higher sales in the performance gases business; average selling prices contributed 7.6%.

Other and Unallocated$2.1M+52.2% YoY

Sales of products outside reportable segments and other minor business activities.

Largest Expense Items

Cost of sales$184.9M+7.5% YoY

Gross margin rose to 36.4% of net sales on sales growth, favorable mix and manufacturing efficiencies, partially offset by higher manufacturing input costs.

Operating expenses$43.3M+5.9% YoY

Higher compensation-related costs of $3,743 and a non-cash impairment charge of $1,915, partially offset by a $4,000 favorable legal settlement.

Interest expense, net$1.9M-26.4% YoY

Lower outstanding borrowings and lower interest rates.

Margins: Gross margin rose to 36.4% of net sales from 35.7% a year earlier, and operating margin rose to 21.5% from 20.4%, driven by sales growth and favorable mix.

Watch Items from the Filing

Inventories rose to $177.0M from $131.4M at December 31, 2025, a 35% increase that absorbed operating cash flow in the nine months.
Revolving loan balance was $124.0M at September 30, 2026, with $526.0M unused; the facility was extended to July 2031 and upsized to $650M.
Management notes heightened Middle East geopolitical tensions could increase energy, raw material and freight costs and disrupt shipping patterns.
Human Nutrition & Health average selling prices contributed -4.4% to segment sales growth in the quarter, indicating pricing pressure offset by volume.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q3 2026

EDGAR

Net Income

Q3 2026

EDGAR

EPS (Diluted)

Q3 2026

EDGAR

Operating Margin

Q3 2026

EDGAR

ROIC

Q3 2026

EDGAR

Free Cash Flow

Q3 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BCPC

Earnings Per Share

13fpro.ai/company/BCPC

Loading ratio trend…

BALCHEM CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$1.0B	$154.8M	20.2%
FY 2024	10-K	$953.7M	$128.5M	19.2%
FY 2023	10-K	$922.4M	$108.5M	17.3%
FY 2022	10-K	$942.4M	$105.4M	15.4%
FY 2021	10-K	$799.0M	$96.1M	16.0%
FY 2020	10-K	$703.6M	$84.6M	15.8%

About BALCHEM CORP (BCPC): stock profile, AI score and financials

BALCHEM CORP (BCPC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BCPC at 63.9/100 on a composite quality score built from its SEC filings, placing it at rank #578 of 2,925 stocks — the top 25% of the AI-ranked universe. BCPC scores in the top quartile across balance sheet strength (85.7). Shareholder dilution risk is elevated at 41.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2026), BALCHEM CORP reports quarterly revenue of $290.7M, net income of $46.7M, an operating margin of 21.5%. Top institutional holders of BCPC by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BCPC trades on the Nasdaq exchange and files with the SEC under CIK 9326. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCPC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BALCHEM CORP directly from SEC EDGAR.

Financials through the period ended Sep 30, 2026SEC EDGAR: CIK 9326 →

BALCHEM CORP BCPC

Top Institutional Holders

What's Driving BCPC's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

BCPC key financials by period

BCPC insiders

Congress trading in BCPC

About BALCHEM CORP (BCPC): stock profile, AI score and financials

BALCHEM CORP BCPC

Top Institutional Holders

What's Driving BCPC's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

BCPC key financials by period

Companies similar to BCPC

BCPC insiders

Congress trading in BCPC

About BALCHEM CORP (BCPC): stock profile, AI score and financials